drugset / Trial / NCT00557557
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
Phase 1
Completed
14 enrolled
David Bartlett
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU in combination with Oxaliplatin delivered via isolated hepatic perfusion.
Timeline
- Start
- 2007-07
- Primary completion
- 2012-03
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 40 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 200 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 900 mg/m2 | Other |